期刊
DIABETES OBESITY & METABOLISM
卷 16, 期 10, 页码 885-890出版社
WILEY
DOI: 10.1111/dom.12280
关键词
metformin; sulphonylureas; type 2 diabetes
资金
- Cardiff University
- Abbott
- ALK
- Astellas
- Diabetes UK
- Engineering and Physical Sciences Research Council
- EASFD
- Ferring
- GSK
- Jenson (Internis)
- Lilly
- Medical Research Council
- Medtronic
- MSD
- National Health Service
- Norgine
- Pfizer
- Sanofi-Aventis
- Shire
- Wyeth
Current clinical guidelines in the USA and the UK recommend first-line glucose-lowering treatment with metformin monotherapy for glucose control in type 2 diabetes, where not contraindicated. Consequently, the proportion of people treated with sulphonylureas is decreasing. The purpose of this commentary is to discuss the risks and benefits associated with sulphonylurea monotherapy versus metformin monotherapy and the evidence that, in comparison with metformin, sulphonylureas cause increased harm to people with type 2 diabetes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据